Company Filing History:
Years Active: 2006-2017
Title: Innovator Profile: Peter Franz Ertl
Introduction
Peter Franz Ertl, based in Stevenage, GB, is a distinguished inventor known for his contributions to the field of immunology. With four patents to his name, Ertl has made significant strides in developing therapeutic solutions targeting TGF-beta signaling pathways. His work holds promise for a range of diseases associated with tissue fibrosis and inflammatory conditions.
Latest Patents
Ertl's latest patents include groundbreaking discoveries centered on nucleic acids that encode immunoglobulins binding to TGF-beta receptor II. His disclosures highlight the development of an anti-TGFbetaRII immunoglobulin single variable domain, boasting an amino acid sequence defined by specific SEQ ID NO:1-28, allowing for minor modifications through substitutions, deletions, or additions. The related polypeptides and pharmaceutical compositions described aim to treat various diseases, such as pulmonary and liver fibrosis, rheumatoid arthritis, ocular disorders, and kidney fibrosis. The implications of these patents extend to conditions like Dupuytren's Contracture, wound healing, scarring reduction, and vascular issues like restenosis.
Career Highlights
Throughout his career, Ertl has been affiliated with notable companies, including Glaxo Group Limited and SmithKline Beecham Corporation. His experience at these organizations has contributed to his innovative projects and research-driven approach to biotechnology and pharmaceuticals.
Collaborations
Ertl has collaborated with several esteemed colleagues in the field, including Andrew Beaton and Caroline Dimech. These collaborations have likely supported the advancement of his research and innovations, fostering a productive environment for scientific exploration.
Conclusion
Peter Franz Ertl exemplifies the impact an inventor can have on medical science and innovation. With his focus on TGF-beta signaling pathways, he continues to pave the way for novel treatments that address critical health challenges. His contributions not only highlight the importance of biotechnology but also inspire future generations of inventors in the field.